Cancer treatment has been revolutionized by new approaches aimed at stimulating the body’s own immune system to fight off tumor cells. These “immunotherapy” approaches have proven successful in many types of cancer, but they are also associated with dangerous inflammation in some patients. This group had previously shown that treating mice with a combination of immune-activating stimuli—anti-CD40 antibodies and interleukin (IL)-2—stimulates tumor-fighting immune cells to eradicate cancer in young mice. In old mice, however, the same treatment triggered deadly inflammation.
As with humans, mice often accumulate fat as they age. Murphy’s group now finds that lethal inflammation in response to anti-CD40/IL-2 immunotherapy is determined more by fat than age. Like old mice, young, obese mice succumbed to lethal inflammation in response to treatment. And putting older mice on diets protected them. This suggests that the results of preclinical immunotherapy studies in mice and humans—primarily performed on young subjects—should be interpreted with caution, particularly as cancer is a disease that predominately affects the elderly.
Mirsoian, A., et al. 2014. J. Exp. Med. doi:10.1084/jem.20140116
About The Journal of Experimental MedicineThe Journal of Experimental Medicine (JEM) is published by The Rockefeller University Press. All editorial decisions on manuscripts submitted are made by active scientists in conjunction with our in-house scientific editors. JEM content is posted to PubMed Central, where it is available to the public for free six months after publication. Authors retain copyright of their published works and third parties may reuse the content for non-commercial purposes under a creative commons license. For more information, please visit www.jem.org .
Research reported in the press release was supported by the National Institutes of Health and the National Institute on Aging.
MEDIA CONTACT
Register for reporter access to contact detailsArticle Multimedia
CITATIONS
Journal of Experimental Medicine, Vol. 211, No. 12; CA0905572; AG034874